Literature DB >> 29078910

RAMP1 signaling improves lymphedema and promotes lymphangiogenesis in mice.

Toshiaki Mishima1, Yoshiya Ito2, Nobuyuki Nishizawa3, Hideki Amano3, Kazutake Tsujikawa4, Kagami Miyaji1, Masahiko Watanabe2, Masataka Majima5.   

Abstract

BACKGROUND: Secondary lymphedema commonly arises as a complication of cancer surgery and radiation treatment; however, the underlying mechanisms are poorly understood. Receptor activity-modifying protein 1 (RAMP1) forms a complex with calcitonin receptor-like receptor to generate the receptor for calcitonin gene-related peptide. The present study examined whether RAMP1 plays a role in increased lymphangiogenesis during secondary lymphedema.
METHODS: A model of lymphedema was generated by surgical removal of pre-existing lymphatic vessels from the subcutaneous tissue on the tails of RAMP1-deficient (RAMP1-/-) mice and their wild-type (WT) counterparts. The maximum diameter of the tail, lymphangiogenesis, and macrophage recruitment were then examined.
RESULTS: Compared with that in WT mice, lymphedema in the tails in RAMP1-/- mice was sustained, with suppressed lymphangiogenesis and reduced expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 at the distal edge of the lesions. The newly formed lymphatic vessels in RAMP1-/- mice were dilated, with impaired lymphatic flow. RAMP1 was expressed by macrophages recruited into edematous tail tissues distal to the wound. The number of macrophages in RAMP1-/- mice was higher than that in WT mice. Expression of messenger RNA encoding M1 macrophage-related genes, including tumor necrosis factor-α and interleukin-1, was higher in RAMP1-/- mice than in WT mice, whereas expression of messenger RNA encoding M2 macrophage genes, including interleukin-10, was lower.
CONCLUSIONS: RAMP1 signaling improves lymphedema and accelerates lymphangiogenesis associated with reduced recruitment of pro-inflammatory macrophages.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymphangiogenesis; Lymphedema; Macrophage; RAMP1

Mesh:

Substances:

Year:  2017        PMID: 29078910     DOI: 10.1016/j.jss.2017.05.124

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  RAMP1 signaling in immune cells regulates inflammation-associated lymphangiogenesis.

Authors:  Seri Tsuru; Yoshiya Ito; Hiromi Matsuda; Kanako Hosono; Tomoyoshi Inoue; Shuji Nakamoto; Chie Kurashige; Toshiaki Mishima; Kazutake Tsujikawa; Hirotsugu Okamoto; Masataka Majima
Journal:  Lab Invest       Date:  2020-01-07       Impact factor: 5.662

2.  RAMP1 in Kupffer cells is a critical regulator in immune-mediated hepatitis.

Authors:  Tomoyoshi Inoue; Yoshiya Ito; Nobuyuki Nishizawa; Koji Eshima; Ken Kojo; Fumisato Otaka; Tomohiro Betto; Sakiko Yamane; Kazutake Tsujikawa; Wasaburo Koizumi; Masataka Majima
Journal:  PLoS One       Date:  2018-11-21       Impact factor: 3.240

3.  Receptor activity-modifying protein 1 regulates mouse skin fibroblast proliferation via the Gαi3-PKA-CREB-YAP axis.

Authors:  Siyuan Yin; Ru Song; Jiaxu Ma; Chunyan Liu; Zhenjie Wu; Guoqi Cao; Jian Liu; Guang Zhang; Huayu Zhang; Rui Sun; Aoyu Chen; Yibing Wang
Journal:  Cell Commun Signal       Date:  2022-04-12       Impact factor: 5.712

4.  Inhibition of receptor activity-modifying protein 1 suppresses the development of endometriosis and the formation of blood and lymphatic vessels.

Authors:  Masako Honda; Yoshiya Ito; Kyoko Hattori; Kanako Hosono; Kazuki Sekiguchi; Kazutake Tsujikawa; Nobuya Unno; Masataka Majima
Journal:  J Cell Mol Med       Date:  2020-09-01       Impact factor: 5.310

Review 5.  Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.

Authors:  Andrew Blumenfeld; Paul L Durham; Alexander Feoktistov; Debbie L Hay; Andrew F Russo; Ira Turner
Journal:  Neurol Ther       Date:  2021-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.